Cargando…

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance

Defects in apoptosis can promote tumorigenesis and impair responses of malignant B cells to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins are key regulators of the intrinsic, mitochondrial apoptotic pathway. Overexpression of antiapoptotic BCL-2 family prote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapoor, Isha, Bodo, Juraj, Hill, Brian T., Hsi, Eric D., Almasan, Alexandru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608616/ https://www.ncbi.nlm.nih.gov/pubmed/33139702 http://dx.doi.org/10.1038/s41419-020-03144-y

Ejemplares similares

Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies
por: Kapoor, Isha, et al.
Publicado: (2021)

Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
por: Kapoor, Isha, et al.
Publicado: (2019)

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
por: Choudhary, G S, et al.
Publicado: (2015)

miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies
por: Al-harbi, Sayer, et al.
Publicado: (2015)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
por: Madanat, Yazan F, et al.
Publicado: (2016)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?
por: Williams, Michelle M., et al.
Publicado: (2015)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2018)

Development of venetoclax for therapy of lymphoid malignancies
por: Zhu, Huayuan, et al.
Publicado: (2017)

Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
por: Lopez, Andrea, et al.
Publicado: (2022)

Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
por: Xu, Wanhong, et al.
Publicado: (2018)

Dual targeting of PI3K and BCL‐2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2022)

Targeted Therapeutic Nanotubes Influence the Viscoelasticity of Cancer Cells to Overcome Drug Resistance
por: Bhirde, Ashwinkumar A., et al.
Publicado: (2014)

Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments
por: Mukherjee, Nabanita, et al.
Publicado: (2016)

SAT-008 Overcoming BCL-2 Resistance in Glucocorticoid-Treated Tumor Lymphoid Cells
por: Bortner, Carl, et al.
Publicado: (2019)

USP14 is a deubiquitinase for Ku70 and critical determinant of non-homologous end joining repair in autophagy and PTEN-deficient cells
por: Sharma, Arishya, et al.
Publicado: (2020)

KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri
por: Kater, Lisa, et al.
Publicado: (2021)

The role of BCL11B in hematological malignancy
por: Huang, Xin, et al.
Publicado: (2012)

Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B cell receptor signaling and tumor growth in diffuse large B cell lymphoma
por: Pore, Debasis, et al.
Publicado: (2015)

Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment
por: Rosko, Ashley E, et al.
Publicado: (2014)

USP14 Regulates DNA Damage Response and Is a Target for Radiosensitization in Non-Small Cell Lung Cancer
por: Sharma, Arishya, et al.
Publicado: (2020)

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

The Therapeutic Potential of Targeting NIK in B Cell Malignancies
por: Haselager, Marco V., et al.
Publicado: (2022)

Overcoming apoptotic resistance afforded by Bcl-2 in lymphoid tumor cells: a critical role for dexamethasone
por: Bortner, Carl D., et al.
Publicado: (2022)

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
por: Lewis, Alexander C., et al.
Publicado: (2022)

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2021)

Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
por: Godwin, P., et al.
Publicado: (2013)

Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA
por: Fairchild, Carter K., et al.
Publicado: (2021)

Targeting SAMHD1: To overcome multiple anti-cancer drugs resistance in hematological malignancies
por: Wang, Tao, et al.
Publicado: (2022)

Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
por: Song, Moo-Kon, et al.
Publicado: (2019)

BCL9/BCL9L in hepatocellular carcinoma: Will it or Wnt it be the next therapeutic target?
por: Moghe, Akshata, et al.
Publicado: (2020)

Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer
por: Lu, Yingjie, et al.
Publicado: (2021)

Overcoming therapeutic resistance to platinum-based drugs by targeting Epithelial–Mesenchymal transition
por: Duan, Xirui, et al.
Publicado: (2022)

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors
por: Masucci, Maria Teresa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d0qncn1akgrhhk83n0kfmf3kbu